| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A chemogenomic approach to drug discovery: focus on cardiovascular diseases
|
Cases, Montserrat
|
|
2009
|
|
9-10 |
p. 479-485
7 p.
|
artikel
|
| 2 |
Advances in the computational development of DNA methyltransferase inhibitors
|
Medina-Franco, José L.
|
|
2011
|
|
9-10 |
p. 418-425
8 p.
|
artikel
|
| 3 |
Allele-selective inhibition of trinucleotide repeat genes
|
Matsui, Masayuki
|
|
2012
|
|
9-10 |
p. 443-450
8 p.
|
artikel
|
| 4 |
A network-based approach to quantifying the impact of biologically active substances
|
Hoeng, Julia
|
|
2012
|
|
9-10 |
p. 413-418
6 p.
|
artikel
|
| 5 |
A new approach to assess drug development performance
|
Rosiello, Alessandro
|
|
2013
|
|
9-10 |
p. 420-427
8 p.
|
artikel
|
| 6 |
Angiotensin-converting enzymes and drug discovery in cardiovascular diseases
|
Shi, Lijun
|
|
2010
|
|
9-10 |
p. 332-341
10 p.
|
artikel
|
| 7 |
A novel selective inhibitor of the phosphodiesterase type 2 isozyme
|
Barlocco, Daniela
|
|
2006
|
|
9-10 |
p. 473-
1 p.
|
artikel
|
| 8 |
An overview of statin-associated proteinuria
|
Tiwari, Atul
|
|
2006
|
|
9-10 |
p. 458-464
7 p.
|
artikel
|
| 9 |
Antibacterial drug discovery and structure-based design
|
Barker, John J.
|
|
2006
|
|
9-10 |
p. 391-404
14 p.
|
artikel
|
| 10 |
Application of LC/MS and related techniques to high-throughput drug discovery
|
Espada, Alfonso
|
|
2008
|
|
9-10 |
p. 417-423
7 p.
|
artikel
|
| 11 |
Application of LC/MS to proteomics studies: current status and future prospects
|
Chen, Guodong
|
|
2009
|
|
9-10 |
p. 465-471
7 p.
|
artikel
|
| 12 |
Application of technologies and parallel chemistry for the generation of actives against biological targets
|
Edwards, P.
|
|
2008
|
|
9-10 |
p. 464-466
3 p.
|
artikel
|
| 13 |
Applications of saturation transfer difference NMR in biological systems
|
Bhunia, Anirban
|
|
2012
|
|
9-10 |
p. 505-513
9 p.
|
artikel
|
| 14 |
A series of case studies: practical methodology for identifying antinociceptive multi-target drugs
|
Pang, Min-Hee
|
|
2012
|
|
9-10 |
p. 425-434
10 p.
|
artikel
|
| 15 |
Assessing the bioequivalence of biosimilars
|
Schellekens, H.
|
|
2009
|
|
9-10 |
p. 495-499
5 p.
|
artikel
|
| 16 |
ATPase inhibitors of heat-shock protein 90, second season
|
Janin, Yves L.
|
|
2010
|
|
9-10 |
p. 342-353
12 p.
|
artikel
|
| 17 |
Biochemical modeling with Systems Biology Graphical Notation
|
Jansson, Andreas
|
|
2010
|
|
9-10 |
p. 365-370
6 p.
|
artikel
|
| 18 |
Biological assay challenges from compound solubility: strategies for bioassay optimization
|
Di, Li
|
|
2006
|
|
9-10 |
p. 446-451
6 p.
|
artikel
|
| 19 |
Biologic and pharmacologic therapies in clinical development for the inflammatory response in COPD
|
Morjaria, Jaymin B.
|
|
2010
|
|
9-10 |
p. 396-405
10 p.
|
artikel
|
| 20 |
Bone morphogenetic proteins and growth differentiation factors as drug targets in cardiovascular and metabolic disease
|
Tobin, James F.
|
|
2006
|
|
9-10 |
p. 405-411
7 p.
|
artikel
|
| 21 |
Brain pericyte plasticity as a potential drug target in CNS repair
|
Lange, Simona
|
|
2013
|
|
9-10 |
p. 456-463
8 p.
|
artikel
|
| 22 |
Bridging solubility between drug discovery and development
|
Di, Li
|
|
2012
|
|
9-10 |
p. 486-495
10 p.
|
artikel
|
| 23 |
Can efficient delivery systems leverage benefits of antioxidants leading to potential medicines?
|
Ravi Kumar, M.N.V.
|
|
2012
|
|
9-10 |
p. 407-408
2 p.
|
artikel
|
| 24 |
Can the flow of medicines be improved? Fundamental pharmacokinetic and pharmacological principles toward improving Phase II survival
|
Morgan, Paul
|
|
2012
|
|
9-10 |
p. 419-424
6 p.
|
artikel
|
| 25 |
Can we vaccinate against depression?
|
Rook, Graham A.W.
|
|
2012
|
|
9-10 |
p. 451-458
8 p.
|
artikel
|
| 26 |
Challenges for chemoinformatics education in drug discovery
|
Wild, David J.
|
|
2006
|
|
9-10 |
p. 436-439
4 p.
|
artikel
|
| 27 |
Characterization of epitopes recognized by monoclonal antibodies: experimental approaches supported by freely accessible bioinformatic tools
|
Clementi, Nicola
|
|
2013
|
|
9-10 |
p. 464-471
8 p.
|
artikel
|
| 28 |
Clusters in the biopharmaceutical industry: toward a new method of analysis
|
Erden, Zeynep
|
|
2011
|
|
9-10 |
p. 450-456
7 p.
|
artikel
|
| 29 |
Communicating the risks and benefits of medicines
|
Schmid, Esther F.
|
|
2007
|
|
9-10 |
p. 355-364
10 p.
|
artikel
|
| 30 |
Compilation of 222 drugs’ plasma protein binding data and guidance for study designs
|
Zhang, Fengling
|
|
2012
|
|
9-10 |
p. 475-485
11 p.
|
artikel
|
| 31 |
Computational modeling of biologically active molecules using NMR spectra
|
Beger, Richard D.
|
|
2006
|
|
9-10 |
p. 429-435
7 p.
|
artikel
|
| 32 |
Consensus scoring for protein–ligand interactions
|
Feher, Miklos
|
|
2006
|
|
9-10 |
p. 421-428
8 p.
|
artikel
|
| 33 |
Contact lenses in ocular therapeutics
|
Gupta, Himanshu
|
|
2012
|
|
9-10 |
p. 522-527
6 p.
|
artikel
|
| 34 |
Contents
|
|
|
2010
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 35 |
Contents
|
|
|
2010
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 36 |
Contents
|
|
|
2008
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 37 |
Contents
|
|
|
2013
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 38 |
Contents
|
|
|
2013
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 39 |
Contents
|
|
|
2012
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 40 |
Contents
|
|
|
2012
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 41 |
Contents page 2
|
|
|
2009
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 42 |
Contents page 1
|
|
|
2009
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 43 |
Contents page 2
|
|
|
2011
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 44 |
Contents page 1
|
|
|
2011
|
|
9-10 |
p. i-
1 p.
|
artikel
|
| 45 |
Crowd computing: using competitive dynamics to develop and refine highly predictive models
|
Bentzien, Jörg
|
|
2013
|
|
9-10 |
p. 472-478
7 p.
|
artikel
|
| 46 |
Design and engineering of nanogels for cancer treatment
|
Yallapu, Murali Mohan
|
|
2011
|
|
9-10 |
p. 457-463
7 p.
|
artikel
|
| 47 |
Designing transient binding drugs: A new concept for drug discovery
|
Ohlson, Sten
|
|
2008
|
|
9-10 |
p. 433-439
7 p.
|
artikel
|
| 48 |
Diary (DRUDIS_34)
|
|
|
2006
|
|
9-10 |
p. 474-
1 p.
|
artikel
|
| 49 |
Diary May 2007
|
|
|
2007
|
|
9-10 |
p. 427-
1 p.
|
artikel
|
| 50 |
Discussions in Geneva, demonstrations in Delhi: why incentives for drug innovation need reviewing
|
Ford, Nathan
|
|
2007
|
|
9-10 |
p. 349-351
3 p.
|
artikel
|
| 51 |
Does process excellence handcuff drug development?
|
Koenig, Jochen
|
|
2011
|
|
9-10 |
p. 377-381
5 p.
|
artikel
|
| 52 |
Drug discovery: selecting the optimal approach
|
Sams-Dodd, Frank
|
|
2006
|
|
9-10 |
p. 465-472
8 p.
|
artikel
|
| 53 |
Dundee: discovering life sciences
|
Tasker, Hilary
|
|
2006
|
|
9-10 |
p. 379-382
4 p.
|
artikel
|
| 54 |
Edinburgh Science Triangle: visionary initiative to serve the next generation of life scientists
|
Moore, Jon
|
|
2006
|
|
9-10 |
p. 383-386
4 p.
|
artikel
|
| 55 |
Editorial Board
|
|
|
2008
|
|
9-10 |
p. iii-
1 p.
|
artikel
|
| 56 |
Functional human tissue assays
|
Hillier, Chris
|
|
2007
|
|
9-10 |
p. 382-388
7 p.
|
artikel
|
| 57 |
Glasgow and the West of Scotland region – bioscience buds beginning to bloom
|
O’Neill, Michael F.
|
|
2006
|
|
9-10 |
p. 387-390
4 p.
|
artikel
|
| 58 |
Harnessing bioinformatics to discover new vaccines
|
Davies, Matthew N.
|
|
2007
|
|
9-10 |
p. 389-395
7 p.
|
artikel
|
| 59 |
HCV protease inhibitor telaprevir: phase II clinical results
|
Peese, Kevin
|
|
2010
|
|
9-10 |
p. 406-
1 p.
|
artikel
|
| 60 |
Heparanase: a universal immunotherapeutic target in human cancers
|
Zhang, Ya-Fei
|
|
2011
|
|
9-10 |
p. 412-417
6 p.
|
artikel
|
| 61 |
Human metabolic network reconstruction and its impact on drug discovery and development
|
Ma, Hongwu
|
|
2008
|
|
9-10 |
p. 402-408
7 p.
|
artikel
|
| 62 |
Immunogenicity risk management for commercial advantage
|
Schwabe, Nikolai
|
|
2013
|
|
9-10 |
p. 417-419
3 p.
|
artikel
|
| 63 |
Impact of new technologies for cellular screening along the drug value chain
|
Möller, Clemens
|
|
2010
|
|
9-10 |
p. 384-390
7 p.
|
artikel
|
| 64 |
Implementation of BacMam virus gene delivery technology in a drug discovery setting
|
Kost, Thomas A.
|
|
2007
|
|
9-10 |
p. 396-403
8 p.
|
artikel
|
| 65 |
Improved preclinical safety assessment using micro-BAL devices: the potential impact on human discovery and drug attrition
|
Giri, Shibashish
|
|
2011
|
|
9-10 |
p. 382-397
16 p.
|
artikel
|
| 66 |
Insights for the development of specific kinase inhibitors by targeted structural genomics
|
Fedorov, Oleg
|
|
2007
|
|
9-10 |
p. 365-372
8 p.
|
artikel
|
| 67 |
Jochen Salfeld talks about HUMIRA® and the development of biological therapies at Abbott
|
Carney, Steve
|
|
2007
|
|
9-10 |
p. 352-354
3 p.
|
artikel
|
| 68 |
Kinase activators as a novel class of antidiabetic agents
|
Castro, Ana
|
|
2012
|
|
9-10 |
p. 528-529
2 p.
|
artikel
|
| 69 |
Learning lessons from drugs that have recently entered the market
|
Teague, Simon J.
|
|
2011
|
|
9-10 |
p. 398-411
14 p.
|
artikel
|
| 70 |
Logic models of pathway biology
|
Watterson, Steven
|
|
2008
|
|
9-10 |
p. 447-456
10 p.
|
artikel
|
| 71 |
Medicinal chemistry strategies in follow-on drug discovery
|
Zhao, Hongyu
|
|
2009
|
|
9-10 |
p. 516-522
7 p.
|
artikel
|
| 72 |
New perspectives on the impact of cytochrome P450 3A expression for pediatric pharmacology
|
Stevens, Jeffrey C.
|
|
2006
|
|
9-10 |
p. 440-445
6 p.
|
artikel
|
| 73 |
New promising drug targets in cancer- and metastasis-initiating cells
|
Mimeault, Murielle
|
|
2010
|
|
9-10 |
p. 354-364
11 p.
|
artikel
|
| 74 |
Non-coding RNAs and new opportunities for the private sector
|
Costa, Fabrício F.
|
|
2009
|
|
9-10 |
p. 446-452
7 p.
|
artikel
|
| 75 |
Nonprofit drugs as the salvation of the world's healthcare systems: the case of Antabuse (disulfiram)
|
Cvek, Boris
|
|
2012
|
|
9-10 |
p. 409-412
4 p.
|
artikel
|
| 76 |
Organometallic compounds in oncology: implications of novel organotins as antitumor agents
|
Alama, Angela
|
|
2009
|
|
9-10 |
p. 500-508
9 p.
|
artikel
|
| 77 |
Patent holdings of US biotherapeutic companies in major markets
|
Sebastian, Teena E.
|
|
2009
|
|
9-10 |
p. 442-445
4 p.
|
artikel
|
| 78 |
Peter Ghazal talks about his vision for the Scottish Centre for Genomic Technology and Informatics
|
Knies-Bamforth, Ulrike
|
|
2006
|
|
9-10 |
p. 376-378
3 p.
|
artikel
|
| 79 |
Pharmacogenetics—pivotal to the future of the biopharmaceutical industry
|
Foot, Elizabeth
|
|
2010
|
|
9-10 |
p. 325-327
3 p.
|
artikel
|
| 80 |
Pharmacological modulation of the leukotriene pathway in allergic airway disease
|
Montuschi, Paolo
|
|
2007
|
|
9-10 |
p. 404-412
9 p.
|
artikel
|
| 81 |
Physical layout of workspace: a driver for productivity in drug discovery
|
Ullman, Fredrik
|
|
2008
|
|
9-10 |
p. 374-378
5 p.
|
artikel
|
| 82 |
Placebo: new insights into an old enigma
|
Ernst, Edzard
|
|
2007
|
|
9-10 |
p. 413-418
6 p.
|
artikel
|
| 83 |
Product-related research: how research can contribute to successful life-cycle management
|
Sandner, Peter
|
|
2008
|
|
9-10 |
p. 457-463
7 p.
|
artikel
|
| 84 |
Progress and problems in the exploration of therapeutic targets
|
Zheng, Chanjuan
|
|
2006
|
|
9-10 |
p. 412-420
9 p.
|
artikel
|
| 85 |
Progress in corticotropin-releasing factor-1 antagonist development
|
Zorrilla, Eric P.
|
|
2010
|
|
9-10 |
p. 371-383
13 p.
|
artikel
|
| 86 |
Protein interaction predictions from diverse sources
|
Liu, Yin
|
|
2008
|
|
9-10 |
p. 409-416
8 p.
|
artikel
|
| 87 |
PTP1B as a drug target: recent developments in PTP1B inhibitor discovery
|
Zhang, Sheng
|
|
2007
|
|
9-10 |
p. 373-381
9 p.
|
artikel
|
| 88 |
Quantitative characterization of non-contact microdispensing technologies for the sub-microliter range
|
Bammesberger, Stefan
|
|
2013
|
|
9-10 |
p. 435-446
12 p.
|
artikel
|
| 89 |
Recent progress in antiretrovirals – lessons from resistance
|
Adamson, Catherine S.
|
|
2008
|
|
9-10 |
p. 424-432
9 p.
|
artikel
|
| 90 |
Recent progress toward biomarker identification in osteoarthritis
|
De Ceuninck, Frédéric
|
|
2011
|
|
9-10 |
p. 443-449
7 p.
|
artikel
|
| 91 |
Schistosomes—proteomics studies for potential novel vaccines and drug targets
|
DeMarco, Ricardo
|
|
2009
|
|
9-10 |
p. 472-478
7 p.
|
artikel
|
| 92 |
Scottish life sciences outlook for 2006
|
Snowden, Ken
|
|
2006
|
|
9-10 |
p. 373-375
3 p.
|
artikel
|
| 93 |
Selective targeting of DPC4 (deleted in pancreatic cancer locus 4)-deficient pancreatic cancer cells
|
Westwell, Andrew D.
|
|
2007
|
|
9-10 |
p. 426-
1 p.
|
artikel
|
| 94 |
Shifting from the single to the multitarget paradigm in drug discovery
|
Medina-Franco, José L.
|
|
2013
|
|
9-10 |
p. 495-501
7 p.
|
artikel
|
| 95 |
Small molecule drug discovery for Huntington's Disease
|
Fecke, Wolfgang
|
|
2009
|
|
9-10 |
p. 453-464
12 p.
|
artikel
|
| 96 |
Small organic molecules that modulate gene transcription
|
Jung, Dongju
|
|
2006
|
|
9-10 |
p. 452-457
6 p.
|
artikel
|
| 97 |
State-of-the-art in ligand-based virtual screening
|
Ripphausen, Peter
|
|
2011
|
|
9-10 |
p. 372-376
5 p.
|
artikel
|
| 98 |
Systems chemical biology and the Semantic Web: what they mean for the future of drug discovery research
|
Wild, David J.
|
|
2012
|
|
9-10 |
p. 469-474
6 p.
|
artikel
|
| 99 |
Targeting cancer-initiating cell drug-resistance: a roadmap to a new-generation of cancer therapies?
|
Alama, Angela
|
|
2012
|
|
9-10 |
p. 435-442
8 p.
|
artikel
|
| 100 |
Targeting VEGF signalling via the neuropilin co-receptor
|
Djordjevic, Snezana
|
|
2013
|
|
9-10 |
p. 447-455
9 p.
|
artikel
|
| 101 |
TGR5: an emerging bile acid G-protein-coupled receptor target for the potential treatment of metabolic disorders
|
Tiwari, Atul
|
|
2009
|
|
9-10 |
p. 523-530
8 p.
|
artikel
|
| 102 |
The AhR twist: ligand-dependent AhR signaling and pharmaco-toxicological implications
|
Guyot, Erwan
|
|
2013
|
|
9-10 |
p. 479-486
8 p.
|
artikel
|
| 103 |
The effect of inflammation on drug metabolism: a focus on pediatrics
|
Vet, Nienke J.
|
|
2011
|
|
9-10 |
p. 435-442
8 p.
|
artikel
|
| 104 |
The histamine H3 receptor as a therapeutic drug target for CNS disorders
|
Gemkow, Mark J.
|
|
2009
|
|
9-10 |
p. 509-515
7 p.
|
artikel
|
| 105 |
The innovative medicines initiative: a pre-competitive initiative to enhance the biomedical science base of Europe to expedite the development of new medicines for patients
|
Hunter, A. Jackie
|
|
2008
|
|
9-10 |
p. 371-373
3 p.
|
artikel
|
| 106 |
The nasty surprise of a complex drug–drug interaction
|
Bode, Chris
|
|
2010
|
|
9-10 |
p. 391-395
5 p.
|
artikel
|
| 107 |
Therapeutic potential for novel ultra long-acting β2-agonists in the management of COPD: biological and pharmacological aspects
|
Malerba, Mario
|
|
2012
|
|
9-10 |
p. 496-504
9 p.
|
artikel
|
| 108 |
The road ahead for large pharma: long-term science and innovation
|
Lundberg, Jan M.
|
|
2009
|
|
9-10 |
p. 439-441
3 p.
|
artikel
|
| 109 |
The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME–Tox)
|
Szakács, Gergely
|
|
2008
|
|
9-10 |
p. 379-393
15 p.
|
artikel
|
| 110 |
The role of cocrystals in pharmaceutical science
|
Shan, Ning
|
|
2008
|
|
9-10 |
p. 440-446
7 p.
|
artikel
|
| 111 |
The role of translational bioinformatics in drug discovery
|
Buchan, Natalie S.
|
|
2011
|
|
9-10 |
p. 426-434
9 p.
|
artikel
|
| 112 |
The seven types of drug discovery waste: toward a new lean for the drug industry
|
Uitdehaag, Joost C.M.
|
|
2011
|
|
9-10 |
p. 369-371
3 p.
|
artikel
|
| 113 |
Towards Virtual Knowledge Broker services for semantic integration of life science literature and data sources
|
Harrow, Ian
|
|
2013
|
|
9-10 |
p. 428-434
7 p.
|
artikel
|
| 114 |
Translational research in the pharmaceutical industry: from theory to reality
|
Sultana, Stefan R.
|
|
2007
|
|
9-10 |
p. 419-425
7 p.
|
artikel
|
| 115 |
Translational research: the changing landscape of drug discovery
|
Fishburn, C. Simone
|
|
2013
|
|
9-10 |
p. 487-494
8 p.
|
artikel
|
| 116 |
Translational semantics and infrastructure: another search for the emperor's new clothes?
|
Mullane, Kevin
|
|
2012
|
|
9-10 |
p. 459-468
10 p.
|
artikel
|
| 117 |
Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies
|
Esmail, Hanif
|
|
2012
|
|
9-10 |
p. 514-521
8 p.
|
artikel
|
| 118 |
Understanding nuclear receptors using computational methods
|
Ai, Ni
|
|
2009
|
|
9-10 |
p. 486-494
9 p.
|
artikel
|
| 119 |
Use of Benford's law in drug discovery data
|
Orita, Masaya
|
|
2010
|
|
9-10 |
p. 328-331
4 p.
|
artikel
|
| 120 |
Zebrafish: a predictive model for assessing drug-induced toxicity
|
McGrath, Patricia
|
|
2008
|
|
9-10 |
p. 394-401
8 p.
|
artikel
|
Tijdschrift beschrijving